Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study

Jelena Be͉ević, Marc J. Gunter, Renee T. Fortner, Konstantinos K. Tsilidis, Elisabete Weiderpass, N. Charlotte Onland-Moret, Laure Dossus, Anne TjØnneland, Louise Hansen, Kim Overvad, Sylvie Mesrine, Laura Baglietto, Francoise Clavel-Chapelon, Rudolf Kaaks, Krasimira Aleksandrova, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Christina Bamia, Giovanna MasalaClaudia Agnoli, Rosario Tumino, Fulvio Ricceri, Salvatore Panico, H. B. Bueno-de-Mesquita, Petra H. Peeters, Mie Jareid, J. Ramon Quirós, Eric J. Duell, Maria Jose Sánchez, Nerea Larrañaga, Maria Dolores Chirlaque, Aurelio Barricarte, Joana A. Dias, Emily Sonestedt, Annika Idahl, Eva Lundin, Nicholas J. Wareham, Kay Tee Khaw, Ruth C. Travis, Sabina Rinaldi, Isabelle Romieu, Elio Riboli, Melissa A. Merritt

Research output: Contribution to journalArticlepeer-review

Abstract

Background:Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521 330 total participants (approximately 370 000 women) aged 25-70 years at recruitment from 1992 to 2000.Methods:Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.Results:After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (≥5 years use vs never use, HR=0.70, 95% CI=0.50-0.99, P trend =0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.Conclusions:Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.

Original languageEnglish
Pages (from-to)1622-1631
Number of pages10
JournalBritish Journal of Cancer
Volume113
Issue number11
DOIs
Publication statusPublished - Dec 1 2015

Keywords

  • epithelial ovarian cancer
  • menopausal hormone therapy
  • oral contraceptives
  • parity
  • survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study'. Together they form a unique fingerprint.

Cite this